Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MGNX – Macrogenics Inc

Float Short %

6.95

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.42

EPS Last/This Y

-0.64

EPS This/Next Y

-1.07

Price

1.69

Target Price

3.75

Analyst Recom

2.5

Performance Q

6.96

Relative Volume

1.21

Beta

1.63

Ticker: MGNX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25MGNX1.720.150.204559
2025-07-28MGNX1.6850.154.004579
2025-07-29MGNX1.590.160.004604
2025-07-30MGNX1.550.161.374599
2025-07-31MGNX1.570.240.005200
2025-08-01MGNX1.580.240.005180
2025-08-04MGNX1.6350.240.005179
2025-08-05MGNX1.6950.240.005183
2025-08-06MGNX1.620.240.005196
2025-08-07MGNX1.610.246.005296
2025-08-08MGNX1.5450.240.005308
2025-08-11MGNX1.4650.240.575286
2025-08-12MGNX1.4750.2520.005303
2025-08-13MGNX1.670.220.005205
2025-08-14MGNX1.6150.220.005205
2025-08-15MGNX1.5750.220.025205
2025-08-18MGNX1.5250.320.002148
2025-08-19MGNX1.4950.310.002182
2025-08-20MGNX1.490.30999.992170
2025-08-21MGNX1.4450.291.672168
2025-08-22MGNX1.6850.300.002184
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25MGNX1.71142.7- -0.63
2025-07-28MGNX1.69142.7- -0.63
2025-07-29MGNX1.58142.7- -0.63
2025-07-30MGNX1.54142.7- -0.63
2025-07-31MGNX1.56142.7- -0.63
2025-08-01MGNX1.58142.7- -0.63
2025-08-04MGNX1.64142.7- -0.63
2025-08-05MGNX1.69142.7- -0.63
2025-08-06MGNX1.62142.7- -0.63
2025-08-07MGNX1.61142.7- -0.63
2025-08-08MGNX1.54142.7- -0.63
2025-08-11MGNX1.47142.7- -0.63
2025-08-12MGNX1.48142.7- -0.63
2025-08-13MGNX1.66142.7- -0.63
2025-08-14MGNX1.61142.7- -0.63
2025-08-15MGNX1.57142.7- -0.63
2025-08-18MGNX1.52142.7- -0.63
2025-08-19MGNX1.49142.7- -0.63
2025-08-20MGNX1.49142.7- -0.63
2025-08-21MGNX1.44142.7- -0.63
2025-08-22MGNX1.69-136.7- -1.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25MGNX-0.01-5.007.03
2025-07-28MGNX-0.01-12.667.03
2025-07-29MGNX-0.01-12.667.03
2025-07-30MGNX-0.01-12.667.03
2025-07-31MGNX-0.01-12.667.03
2025-08-01MGNX-0.01-12.667.03
2025-08-04MGNX-0.01-12.387.03
2025-08-05MGNX-0.01-12.387.03
2025-08-06MGNX-0.01-12.387.03
2025-08-07MGNX-0.01-12.387.03
2025-08-08MGNX-0.01-12.387.03
2025-08-11MGNX-0.01-12.427.03
2025-08-12MGNX-0.01-12.426.98
2025-08-13MGNX-0.01-12.426.98
2025-08-14MGNX-0.01-12.426.98
2025-08-15MGNX-0.01-12.426.98
2025-08-18MGNX-0.01-19.756.97
2025-08-19MGNX-0.01-19.756.60
2025-08-20MGNX0.00-19.756.60
2025-08-21MGNX5.38-19.756.95
2025-08-22MGNX2.02-19.756.95
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.57

Avg. EPS Est. Current Quarter

-0.33

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

2.02

Institutional Transactions

-19.75

Beta

1.63

Average Sales Estimate Current Quarter

28

Average Sales Estimate Next Quarter

33

Fair Value

Quality Score

38

Growth Score

47

Sentiment Score

17

Actual DrawDown %

95.4

Max Drawdown 5-Year %

-97

Target Price

3.75

P/E

Forward P/E

PEG

P/S

0.65

P/B

2.29

P/Free Cash Flow

EPS

-0.57

Average EPS Est. Cur. Y​

-1.71

EPS Next Y. (Est.)

-2.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-21.99

Relative Volume

1.21

Return on Equity vs Sector %

-102.8

Return on Equity vs Industry %

-89.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

MacroGenics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading